APA Citatie

Bernier, C., Soliman, A., Gravel, M., Dankner, M., Savage, P., Petrecca, K., . . . Roulston, A. (2018). DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs.

Chicago Style citaat

Bernier, Cynthia, et al. "DZ-2384 Has a Superior Preclinical Profile to Taxanes for the Treatment of Triple-negative Breast Cancer and Is Synergistic With Anti-CTLA-4 Immunotherapy." Anticancer Drugs 2018.

MLA citatie

Bernier, Cynthia, et al. "DZ-2384 Has a Superior Preclinical Profile to Taxanes for the Treatment of Triple-negative Breast Cancer and Is Synergistic With Anti-CTLA-4 Immunotherapy." Anticancer Drugs 2018.